ORIXHA

ORIXHA is a MedTech company founded in 2018, dedicated to improving the lives of critical care patients through its innovative total liquid ventilation (TLV) technology, branded as LuncoLive. Established by a team of researchers and clinicians from Quebec and France, ORIXHA focuses on delivering clinical benefits to patients facing life-threatening conditions that current treatments do not adequately address. The company specializes in developing therapeutic medical devices based on its TLV platform. Its flagship product, Vent2Cool, is designed to treat Post Cardiac Arrest Syndrome by inducing ultra-rapid therapeutic hypothermia, cooling the lungs to a protective temperature of 33°C within minutes. This rapid cooling helps protect vital organs from injury. ORIXHA is also developing Vent2Breathe, aimed at treating Acute Respiratory Distress Syndrome (ARDS), and is exploring projects related to breathable liquid reprocessing. ORIXHA's devices are intended for use in emergency and intensive care units, targeting critically ill patients. The company has made significant progress in clinical and regulatory milestones, including securing funding to support its development and validation efforts.

• Employees 13
• Founded 2018